Connected Plant for Pharma Manufacturing
Ensure data integrity and streamline GMP workflows by eliminating paper, multistep data collection/entry SOPs, and unnecessary manual touch points with Connected Plant — unlocking data silos, more informed decision making, and AI/ML adoption. Maintain effortless compliance with 21 CFR Part 11 with a built-in e-sign and review process and extensive audit logging from one UI.
Request a Demo
Connect GMP Instruments to Digital Systems
Built For Workhorse Instruments:
Our platform connects to multi-vendor air particle counters, microbial air samplers, pH meters, balances, zeta potential analyzers and other analytical scientific instruments in GMP/ISO environments and extract their data through each instrument's native communication protocols.
Learn More About Connecting Instruments to Our PlatformEliminate Manual Data Formatting Processes:
Automate Standardization with Our Data Formatting Engine.
Learn More About Automating with Connected PlantIntegrate with Existing Digital Systems, SOPs and Compliance Parameters:
Critical data securely synchronizes to LIMS, MES, or QMS without changing any existing SOPs. We build around the infrastructure that's already in place.
Learn More About Integrating With Connected PlantBenefits of Connected Plant in Pharma Manufacturing:
Faster Pipelines with Better Data Integrity:
Accelerate data flow from GMP data sources to Digital Systems and maintain the highest level of data integrity by completely eliminating the potential for human error through manual data collection and data entry.
Enable AI/ML Insights:
Breaking down data silos and getting consistent, formatted data enables decision makers to utilize AI and ML to improve manufacturing workflows.
Enhanced Contamination Control:
Remote operation reduces human entry into controlled environments, minimizing contamination risk while maintaining continuous monitoring of critical parameters.
FDA Inspection Ready at All Times:
Organized digital data with complete audit trails makes regulatory inspections smoother and faster, reducing facility downtime during FDA visits.
Accelerated Batch Release:
Digitized workflows eliminate delays in data review and approval processes, enabling faster batch disposition and release decisions to get products to market sooner.
Reduced Cost of Quality:
Minimize CAPA investigations, deviation reports, and failed batch costs by eliminating human error in data collection and maintaining consistent, traceable processes.